Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has received approval from China’s National Medical Products Administration for the drug registration of Norepinephrine Bitartrate Injection, a chemical Category 3 product. The injection is approved for restoring blood pressure in acute hypotensive states, as adjunctive therapy in cardiac arrest and for maintaining blood pressure after resuscitation, and as an adjunct to volume replacement in hypovolemic shock to temporarily preserve cerebral and coronary perfusion, expanding the group’s critical-care treatment portfolio and reinforcing its position in China’s hospital and emergency drug market.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a major Chinese healthcare and pharmaceutical group involved in the research, development, manufacturing and distribution of medicines and medical products, with operations spanning both domestic and overseas markets through a portfolio of subsidiaries.
Average Trading Volume: 4,345,465
Technical Sentiment Signal: Hold
Current Market Cap: HK$76.32B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.